Summary & Overview
HCPCS G8967: FDA-Approved Oral Anticoagulant Prescribed
HCPCS Level II code G8967 documents that an FDA-approved oral anticoagulant has been prescribed. This code is used in outpatient settings to capture that a patient has been started on or maintained with an approved oral anticoagulant agent, which has national clinical significance given the widespread use of these agents for stroke prevention, venous thromboembolism treatment and secondary prevention of thrombotic events. Proper capture of G8967 supports care coordination, medication reconciliation, quality reporting and appropriate benefit administration across payers.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of the code's clinical intent and service context, typical sites of service, and payer coverage landscape. The publication outlines benchmarking and billing considerations, common modifiers used with the service line, and where to find related coding guidance. It also highlights gaps where input data is not available and directs readers to combine this code-level detail with clinical documentation for claims accuracy and program compliance.
Billing Code Overview
HCPCS Level II code G8967 indicates that an FDA-approved oral anticoagulant is prescribed. The code represents documentation that a patient has been prescribed an oral anticoagulant agent approved by the U.S. Food and Drug Administration.
Service Type: Medication prescription / pharmacologic therapy management
Typical Site of Service: Outpatient ambulatory settings, including primary care offices, cardiology clinics, anticoagulation clinics, and other outpatient specialty clinics where prescriptions are initiated or documented.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with nonvalvular atrial fibrillation or venous thromboembolism who is being prescribed an FDA‑approved oral anticoagulant (e.g., apixaban, rivaroxaban, dabigatran, edoxaban). The patient presents to an outpatient cardiology or internal medicine clinic for initiation or continuation of anticoagulation. Clinical workflow includes medication reconciliation, assessment of stroke and bleeding risk (CHA2DS2‑VASc, HAS‑BLED), review of renal and hepatic function, evaluation of drug interactions and contraindications, patient counseling on adherence and bleeding precautions, and documentation of the prescription in the medical record. Laboratory testing (serum creatinine, CBC, liver function tests) is obtained or reviewed prior to prescribing; follow‑up is arranged to reassess renal function and adherence. The service captured by billing code G8967 documents that an FDA‑approved oral anticoagulant was prescribed during the encounter. Typical sites of service are outpatient clinic, cardiology office, primary care office, or anticoagulation clinic. Modifier use may reflect unusual circumstances (e.g., AS for anesthesia when a procedure requires sedation, or clinical trial modifiers for research‑related encounters). Common payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare depending on patient coverage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |